Literature DB >> 19246099

Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece).

H C Maltezou1, P Giakkoupi, A Maragos, M Bolikas, V Raftopoulos, H Papahatzaki, G Vrouhos, V Liakou, A C Vatopoulos.   

Abstract

Starting in May 2007, an ongoing outbreak of infections due to carbapenem resistant KPC-2-producing Klebsiella pneumoniae occurred in a tertiary care hospital in Crete (Greece). The outbreak involved 22 patients, none of whom had travelled in a country with known high prevalence of such isolates. KPC-producing K. pneumoniae strains were mainly isolated from patients admitted in the Intensive Care Unit, on mechanical ventilation, with prolonged hospitalization, prolonged administration of antibiotics, and prolonged administration of carbapenems. Clinical diagnoses were: pneumonia (62% of cases), surgical site infection (19%), bacteremia (9.5%), urinary tract infection (4.7%), and peritonitis (4.7%). Overall, 61 KPC-producing K. pneumoniae isolates were recovered, mainly from the respiratory tract (59.1%), catheter tip (22.7%), surgical site (18.2%), and blood (18.2%). Among 16 patients for whom therapeutic data were available, 14 (87.5%) were treated with a combination of colistin and/or tigecycline and/or garamycin. Clinical failure was noted in 22.2% of 18 patients available for assessment of clinical outcome, and microbiologic failure in 87.5% of 8 patients available for assessment of microbiologic outcome. In conclusion, an outbreak of KPC-producing K. pneumoniae infections has occurred in a tertiary care hospital in Greece, with significant associated morbidity and mortality. Prospective studies are required to evaluate the available therapeutic options for these infections. Our efforts should focus on rational use of available antibiotics, enhancement of infection control measures, and implementation of active antibiotic resistance surveillance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19246099     DOI: 10.1016/j.jinf.2009.01.010

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  53 in total

1.  Use of ChromID extended-spectrum beta-lactamase medium for detecting carbapenemase-producing Enterobacteriaceae.

Authors:  Amélie Carrër; Nicolas Fortineau; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2010-03-17       Impact factor: 5.948

2.  In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.

Authors:  Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series.

Authors:  Rita Murri; Barbara Fiori; Teresa Spanu; Ilaria Mastrorosa; Francesca Giovannenze; Francesco Taccari; Claudia Palazzolo; Giancarlo Scoppettuolo; Giulio Ventura; Maurizio Sanguinetti; Roberto Cauda; Massimo Fantoni
Journal:  Infection       Date:  2017-02-09       Impact factor: 3.553

4.  Antibiotic therapy in neonatal and pediatric septic shock.

Authors:  Rajesh K Aneja; Ruby Varughese-Aneja; Carol G Vetterly; Joseph A Carcillo
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

5.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

Review 6.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

7.  ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Eliana S Armstrong; Yuvraj Choudhary; James B Aggen; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

8.  Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.

Authors:  Jae H Hong; Cornelius J Clancy; Shaoji Cheng; Ryan K Shields; Liang Chen; Yohei Doi; Yanan Zhao; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

Review 9.  Carbapenemase-producing Enterobacteriaceae.

Authors:  Yohei Doi; David L Paterson
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

10.  In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.

Authors:  Thérèse Stachyra; Premavathy Levasseur; Marie-Claude Péchereau; Anne-Marie Girard; Monique Claudon; Christine Miossec; Michael T Black
Journal:  J Antimicrob Chemother       Date:  2009-06-02       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.